George Perry, PhD, University of Texas at San Antonio, San Antonio, TX, discusses the limitations of our current understanding of Alzheimer’s disease (AD) in utilizing gene-editing technology. Medicine has prospered with diseases from external sources – and is beginning to make headway with diseases of defect. AD is an example of both chronic disease and defect. Genetic manipulation will eventually help benefit the treatment of diseases across the board, yet there are still many unknowns. Understanding diseases of aging like cancers, AD, heart disease, etc., are vital for public health, but progress has only been made in a few of these. Although gene editing has been performed in cell and transgenic models, it is challenging to translate this to a human model due to the complexity of sporadic AD. This interview took place during the 2022 World Congress on Controversies in Neurology (CONy) meeting.
Synaptogenix –Chair of Scientific Advisory Board and Equity Nervgen—Scientific Advisory Board Neurotez- Equity